[CAS NO. 496775-61-2]  Eltrombopag

Eltrombopag (0.002-50 μM; 4 h) possesses activity in murine BAF3 cells transfected with the luciferase reporter gene ^[1] .
Eltrombopag (30 μM; 120 min) affects the activates of p-STAT5 in N2C-Tpo cells ^[1] .
Eltrombopag (30 μM; 120 min) activates p-STAT5 in megakaryocytes ^[1] .
Eltrombopag (0.1 nM-10 μM; 30 min) stimulates proliferation of BAF3/hTpoR cells ^[1] .
Eltrombopag (0.03-3 μM; 10 days) increases the differentiation of bone marrow CD34 ⁺ cells into CD41 ⁺ megakaryocytes ^[1] .
Eltrombopag (0-3 μM; 72 h) affects N2C-Tpo cell apoptosis ^[1] .
Eltrombopag efficiently inhibits Pneumococcal growth with MIC ₅₀ of 0.3 mg/L, but shows no activity against Gram-negative bacteria ^[3] .
Eltrombopag (0-200 mg/L; 24 h; Caco-2 and HepG2 cells) inhibits Staphylococcus aureus growth with an MIC ₅₀ of 1.5 mg/L, and exhibits higher potency when co-treats with Vancomycin (HY-B0671) with an MIC ₅₀ of 1.2 mg/L ^[3] .
Eltrombopag (0 or 10 μg/mL; 72 h) significantly induces G0/G1 phase arrest in Huh7 cells ^[5] .
Eltrombopag (0.1-100 μg/mL; 72 h) exhibits anti-proliferative activity against HCC cell lines ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.